(lp0
S"Pluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a ... GlobeNewswire  - Oct 25, 2016 HAIFA, Israel, Oct. 25, 2016  -- Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced it has signed a term sheet for an investment of approximately&nbsp;...Israel's Pluristem to get $30m Chinese investment - The Times of Israel"
p1
aS'Pluristem Therapeutics - A Potential Beneficiary Of The 21st Century Cures Act Seeking Alpha - Dec 16, 2016 An accelerated development time frame is obviously huge news for a company like Pluristem since it greatly reduces the amount of cash burn required  and provides a leg-up on competition.'
p2
aS'FBR Capital Analyst Bullish on Pluristem Therapeutics Inc.  Following ... Smarter Analyst - Jul 11, 2016 FBR Capital analyst Vernon Bernardino weighed in on Pluristem Therapeutics Inc.  following the an announcement that the company plans to initiate a Phase I trial to investigate its PLX-R18 drug.'
p3
aS"Pluristem Announces Closing of Bought Offering and Underwriter's Exercise in ... GlobeNewswire  - Jan 25, 2017 HAIFA, Israel, Jan. 25, 2017  -- Pluristem Therapeutics Inc.   announced today that H.C."
p4
aS'Will Pluristem Therapeutics Inc.  Succeed in CLI Where Sanofi SA ... Market Exclusive - Aug 11, 2016 Pluristem Therapeutics Inc.  has achieved just that, hitting for the cycle so to speak, with two accelerated approval pathways for its PLX-PAD placental cell treatment for critical limb ischemia .'
p5
aS"Exclusive Interview With Pluristem Therapeutics Inc. President ... Market Exclusive - Nov 29, 2016 I was appointed Pluristem's President and Chief Operating Officer in 2014. Prior to that, I served as Pluristem's Chief Financial Officer and Secretary since 2006, and Executive Vice President since 2013. Before joining Pluristem, I was the Chief ..."
p6
aS'Pluristem Announces Bought Deal Offering GlobeNewswire  - Jan 19, 2017 HAIFA, Israel, Jan. 19, 2017  -- Pluristem Therapeutics Inc.   announced today that it has entered into an underwriting agreement with H.C.Pluristem Therapeutics  Increases Bought Deal Offering of Common Stock ... - StreetInsider.comMaxim Group Reiterates $3.00 Price Target for Pluristem Therapeutics Inc.  - The Cerbat Gem'
p7
aS'Pluristem Therapeutics Inc Realized Volatility Hits An Inflection Point CML News - Mar 14, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories  based on a large number of data interactions for Pluristem Therapeutics Inc  . We examine the little used gem of daily stock volatility over a ...'
p8
aS'Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage Seeking Alpha  - Feb 2, 2015 Pluristem Therapeutics Inc.  is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.'
p9
aS"Why Pluristem Therapeutics Inc. Is So Undervalued  The Market Is Ignoring ... Market Exclusive - Nov 3, 2016 Market Exclusive has been following Pluristem Therapeutics Inc.  since July, and for reasons that we will detail below, we see the stock as extremely undervalued, and we don't use that phrase flippantly, or often."
p10
a.